<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To investigate the occurrence of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e>, a rabbit embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> model was used for the continuous monitoring of the change of the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Red <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was directly injected into the internal carotid artery via the catheter inserted into the external carotid artery </plain></SENT>
<SENT sid="2" pm="."><plain>The migration of the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> into the middle cerebral artery was judged as the completion of an embolism </plain></SENT>
<SENT sid="3" pm="."><plain>The change of the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> and its movement was observed for a period of two hours </plain></SENT>
<SENT sid="4" pm="."><plain>The experimental group received recombinant tissue plasminogen activator (<z:chebi fb="6" ids="15702,53394">TPA</z:chebi>) for the thrombolysis while the control group received a saline solution for 30 minutes </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in the middle cerebral artery was continuously observed for two and a half hours </plain></SENT>
<SENT sid="6" pm="."><plain>1 </plain></SENT>
<SENT sid="7" pm="."><plain>There was a spontaneous movement of the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> during the first two hours in six out of 18 cases </plain></SENT>
<SENT sid="8" pm="."><plain>One case showed a spontaneous regression in size at the migration site </plain></SENT>
<SENT sid="9" pm="."><plain>2 </plain></SENT>
<SENT sid="10" pm="."><plain>White <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation occurred around the <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in eight out of 18 cases </plain></SENT>
<SENT sid="11" pm="."><plain>3 </plain></SENT>
<SENT sid="12" pm="."><plain>In the <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> injected group, thrombolysis was observed in nine out of ten rabbits </plain></SENT>
<SENT sid="13" pm="."><plain>The accompanied white <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was also found to be degraded </plain></SENT>
<SENT sid="14" pm="."><plain>However, after the <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> injection, white <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was newly formed during the lysis of red <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>4 </plain></SENT>
<SENT sid="16" pm="."><plain>In the saline solution injected control group, only partial recanalization occurred in three out of eight rabbits </plain></SENT>
<SENT sid="17" pm="."><plain>There was no white <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in the control group </plain></SENT>
<SENT sid="18" pm="."><plain>5 </plain></SENT>
<SENT sid="19" pm="."><plain>There was no significant difference in the degree of Evans blue exudation between these two groups </plain></SENT>
<SENT sid="20" pm="."><plain>Secondary activation of the platelet function easily occurred by the change of the blood flow during <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> migration and also thrombolysis </plain></SENT>
<SENT sid="21" pm="."><plain>In conclusion, thrombolysis therapy may be more effective when <z:chebi fb="6" ids="15702,53394">TPA</z:chebi> is administered in conjunction with the suppression of platelet function </plain></SENT>
</text></document>